Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 135

1.

BTLA Expression on Th1, Th2 and Th17 Effector T-Cells of Patients with Systemic Lupus Erythematosus Is Associated with Active Disease.

Oster C, Wilde B, Specker C, Sun M, Kribben A, Witzke O, Dolff S.

Int J Mol Sci. 2019 Sep 11;20(18). pii: E4505. doi: 10.3390/ijms20184505.

2.

Expression pattern of co-inhibitory molecules on CMV-specific T-cells in lung transplant patients.

Bessa V, Sun M, Meier M, Zeng Y, Xu S, Dolff S, Sommerwerck U, Korth J, Taube C, Aigner C, Kamler M, Kribben A, Lindemann M, Witzke O, Wilde B.

Clin Immunol. 2019 Sep 6;208:108258. doi: 10.1016/j.clim.2019.108258. [Epub ahead of print]

PMID:
31499181
3.

Health outcome of older hospitalized patients in internal medicine environments evaluated by Identification of Seniors at Risk (ISAR) screening and geriatric assessment.

Scharf AC, Gronewold J, Dahlmann C, Schlitzer J, Kribben A, Gerken G, Rassaf T, Kleinschnitz C, Dodel R, Frohnhofen H, Hermann DM.

BMC Geriatr. 2019 Aug 14;19(1):221. doi: 10.1186/s12877-019-1239-3.

4.

HLA-E Polymorphism Determines Susceptibility to BK Virus Nephropathy after Living-Donor Kidney Transplant.

Rohn H, Michita RT, Schramm S, Dolff S, Gäckler A, Korth J, Heinemann FM, Wilde B, Trilling M, Horn PA, Kribben A, Witzke O, Rebmann V.

Cells. 2019 Aug 7;8(8). pii: E847. doi: 10.3390/cells8080847.

5.

Novel plasma peptide markers involved in the pathology of CKD identified using mass spectrometric approach.

Gajjala PR, Bruck H, Noels H, Heinze G, Ceccarelli F, Kribben A, Saez-Rodriguez J, Marx N, Zidek W, Jankowski J, Jankowski V.

J Mol Med (Berl). 2019 Aug 5. doi: 10.1007/s00109-019-01823-8. [Epub ahead of print]

PMID:
31385015
6.

Measurement of BK-polyomavirus Non-Coding Control Region Driven Transcriptional Activity Via Flow Cytometry.

Korth J, Sertznig H, Moyrer S, Doevelaar AAN, Westhoff TH, Babel N, Witzke O, Kribben A, Dittmer U, Widera M.

J Vis Exp. 2019 Jul 13;(149). doi: 10.3791/59755.

PMID:
31355784
7.

IL-22 production of effector CD4+ T-cells is altered in SLE patients.

Dolff S, Scharpenberg C, Specker C, Kribben A, Witzke O, Wilde B.

Eur J Med Res. 2019 Jul 22;24(1):24. doi: 10.1186/s40001-019-0385-6.

8.

Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.

Friebus-Kardash J, Gäckler A, Kribben A, Witzke O, Wedemeyer H, Treckmann J, Herzer K, Eisenberger U.

Transpl Infect Dis. 2019 Jul 15:e13146. doi: 10.1111/tid.13146. [Epub ahead of print]

PMID:
31306562
9.

High Cardiovascular Risk Profile in Young Patients on the Kidney Transplant Waiting List.

Mülling N, Kallenberg N, Benson S, Dolff S, Kribben A, Reinhardt W.

Transplant Proc. 2019 Jul - Aug;51(6):1717-1726. doi: 10.1016/j.transproceed.2019.04.055. Epub 2019 Jul 10.

PMID:
31301861
10.

Randomized, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun® Optoral (Novartis) under fasting versus fed conditions in patients with stable renal transplants.

Gäckler A, Dolff S, Rohn H, Korth J, Wilde B, Eisenberger U, Mitchell A, Kribben A, Witzke O.

BMC Nephrol. 2019 May 14;20(1):167. doi: 10.1186/s12882-019-1340-z.

11.

B-cell dynamics during experimental endotoxemia in humans.

Brinkhoff A, Zeng Y, Sieberichs A, Dolff S, Shilei X, Sun M, Engler H, Benson S, Korth J, Schedlowski M, Kribben A, Witzke O, Wilde B.

Biosci Rep. 2019 May 17;39(5). pii: BSR20182347. doi: 10.1042/BSR20182347. Print 2019 May 31.

12.

Prevalence of active hepatitis E virus infection and efficacy of ribavirin treatment in renal allograft recipients.

Friebus-Kardash J, Eisenberger U, Ackermann J, Kribben A, Witzke O, Wenzel J, Rohn H, Fiedler M.

Transpl Infect Dis. 2019 Jun;21(3):e13088. doi: 10.1111/tid.13088. Epub 2019 Apr 16.

PMID:
30929308
13.

Evaluation of hemostasis in patients with end-stage renal disease.

Gäckler A, Rohn H, Lisman T, Benkö T, Witzke O, Kribben A, Saner FH.

PLoS One. 2019 Feb 20;14(2):e0212237. doi: 10.1371/journal.pone.0212237. eCollection 2019.

14.

The detection of BKPyV genotypes II and IV after renal transplantation as a simple tool for risk assessment for PyVAN and transplant outcome already at early stages of BKPyV reactivation.

Korth J, Anastasiou OE, Bräsen JH, Brinkhoff A, Lehmann U, Kribben A, Dittmer U, Verheyen J, Wilde B, Ciesek S, Witzke O, Widera M.

J Clin Virol. 2019 Apr;113:14-19. doi: 10.1016/j.jcv.2019.02.002. Epub 2019 Feb 10.

PMID:
30771597
15.

Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function.

Eisenberger U, Friebus-Kardash J, Guberina H, Kribben A, Witzke O, Willuweit K, Gerken G, Herzer K.

Transplant Direct. 2018 Dec 27;5(1):e419. doi: 10.1097/TXD.0000000000000860. eCollection 2019 Jan.

16.

Study Highlights System Deficiencies.

Kribben A.

Dtsch Arztebl Int. 2018 Nov 2;115(44):749. doi: 10.3238/arztebl.2018.0749b. No abstract available.

17.

Dialysis drains as a possible source for carbapenem-resistant pathogens causing an ICU outbreak.

Ross B, Krull M, Rath P, Kribben A, Dopadlik D, Erlemann I, Wiegard-Szramek I, Tyczynski B, Buer J, Herbstreit F.

Infection. 2019 Apr;47(2):233-238. doi: 10.1007/s15010-018-1239-9. Epub 2018 Nov 21.

PMID:
30465327
18.

Impact of immune suppressive agents on the BK-Polyomavirus non coding control region.

Korth J, Anastasiou OE, Verheyen J, Dickow J, Sertznig H, Frericks N, Bleekmann B, Kribben A, Brinkhoff A, Wilde B, Sutter K, Dittmer U, Ciesek S, Witzke O, Widera M.

Antiviral Res. 2018 Nov;159:68-76. doi: 10.1016/j.antiviral.2018.09.013. Epub 2018 Sep 27.

PMID:
30268912
19.

Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab.

Gäckler A, Kaulfuß M, Rohn H, Vogel U, Claus H, Feldkamp T, Kribben A, Witzke O.

Nephrol Dial Transplant. 2018 Jul 9. doi: 10.1093/ndt/gfy225. [Epub ahead of print]

PMID:
29992261
20.

Pro-Inflammatory Th1 and Th17 Cells Are Suppressed During Human Experimental Endotoxemia Whereas Anti-Inflammatory IL-10 Producing T-Cells Are Unaffected.

Brinkhoff A, Sieberichs A, Engler H, Dolff S, Benson S, Korth J, Schedlowski M, Kribben A, Witzke O, Wilde B.

Front Immunol. 2018 May 18;9:1133. doi: 10.3389/fimmu.2018.01133. eCollection 2018.

Supplemental Content

Loading ...
Support Center